Antitachycardia Pacing
Conditions
Brief summary
This study aims to investigate the impact of antitachycardia pacing ( ATP) on the myocardial tissue with respect to its potential micro damage measured by several myocardial markers, especially by high-sensitive TroponinT.
Interventions
DEVICEImplantable Cardioverter Defibrillator
Sponsors
Deutsches Herzzentrum Muenchen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients for de-novo implantation of a transvenous ICD (single chamber, dual chamber or cardiac resynchronization tehrapy) with left pectoral device position and planned apical location of the right ventricular defibrillation electrode.
Exclusion criteria
* Resuscitation, cardiac surgical procedure, acute coronary syndrome, acute myocardial infarction, coronary revascularisation, cardioversion or ablation during the past 4 weeks, if baseline high-sensitive Troponin T is elevated * Known stenosis of coronary vessels with indication for coronary intervention or operative revascularisation * Intracardiac thrombus or general contraindication against ventricular burst stimulation or intraoperative ICD-testing * Atypical lead implantation with indication for defibrillation threshold testing by induction of ventricular fibrillation * Right sided implantation of ICD * Planned electrical cardioversion * Lead explantation or -extraction during procedure * Redo procedure (except of additional implantation of a right ventricular ICD lead) * Present temporary pacemaker electrode * ASA \>= IV or NYHA IV * Cardiogenic shock * Pulmonary embolism, cerebrovascular insult or dialysis in the past 4 weeks * Lack of consent of patient * Minority of patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High sensitive Troponin | 14-20 hours |
Countries
Germany
Outcome results
None listed